| Literature DB >> 19236877 |
Max Crispin1, Thomas A Bowden, Charlotte H Coles, Karl Harlos, A Radu Aricescu, David J Harvey, David I Stuart, E Yvonne Jones.
Abstract
Antibodies contain a conserved glycosylation site that has emerged as a target for the modulation of antibody effector functions. The crystal structure of a biosynthetic intermediate of human IgG1, bearing immature oligomannose-type glycans and reported to display increased antibody-dependent cellular cytotoxicity, demonstrates that glycan engineering can bias the Fc to an open conformation primed for receptor binding.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19236877 DOI: 10.1016/j.jmb.2009.02.033
Source DB: PubMed Journal: J Mol Biol ISSN: 0022-2836 Impact factor: 5.469